| Name | Title | Contact Details |
|---|
Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system (CNS) disorders. Promentis` drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Company`s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.
Our mission at Kelyniam is to apply 3D printing and rapid prototyping technology to create innovative medical products that improve the lives of physicians and their patients.
CanAm Bioresearch is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Genactis is a Fort Washington, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
REDCON1 is a company that creates premium nutritional supplements for athletes of all levels, with the objective of bringing them to the highest state of readiness.